Ansa Biotechnologies Pushes Limits of Complex DNA Synthesis with Launch of New Commercial Products
July 30 2024 - 8:03AM
Business Wire
Only company able to offer ultra-rapid,
assembly-free production of sequences up to 600 bp at scale in
sequence-perfect clonal DNA or faster sequence-verified linear
dsDNA fragment formats
Ansa Biotechnologies, Inc., the trusted partner for complex DNA
synthesis, today announced the commercial availability of its Ansa
Clonal DNA and Ansa DNA Fragments. Ansa is the only company able to
synthesize complete, contiguous DNA oligonucleotides as long as 600
bp without requiring assembly, delivering products as
sequence-perfect clonal DNA or sequence-verified linear
double-stranded DNA fragments.
The launch of the Ansa Clonal DNA and Ansa DNA Fragments follows
the successful completion of the company’s early access program,
which provided researchers worldwide with complex synthetic DNA
sequences that were either previously impossible to produce or
constrained by significant quality shortcomings and
progress-limiting turnaround times. One team of researchers at the
Innovative Genomics Institute (IGI) worked with Ansa to manufacture
DNA sequences with complex features to advance research related to
microbial gene transfer and communities. Founded by Nobel Prize
winner and genome-engineering technology expert Jennifer A. Doudna,
PhD, IGI is a joint effort between the Bay Area’s leading
scientific research institutions, UC Berkeley and UC San Francisco,
with affiliates at UC Davis, Lawrence Berkeley National Laboratory,
Lawrence Livermore National Laboratory, Gladstone Institutes, and
other institutions.
“As we develop technologies to achieve precision microbiome
genetic engineering, we routinely rely on complex DNA sequences,
such as highly repetitive microbial replicons and guide RNA
arrays,” said Jaymin Patel, PhD, Postdoctoral Researcher at IGI and
UC Berkeley. “Ansa was the only company that could deliver these
complex sequences, allowing us to test microbial editing tools that
were previously inaccessible.”
Ansa’s innovative enzymatic DNA synthesis approach eliminates
the need for harsh chemicals and does not damage the molecule as it
is synthesized, enabling the direct synthesis of much longer
strands than is possible with legacy chemical DNA synthesis
techniques. These long constructs allow Ansa’s platform to reliably
manufacture complex DNA elements such as repeats, hairpins, strong
secondary structures, homopolymers, and more. Customers are using
the Ansa platform to gain access to the full range of sequences
found in genomes, which will advance biological engineering and the
development of new therapeutics and sustainable products.
“The DNA synthesis industry has conditioned customers to accept
the disappointment of frequent order rejections, delayed or partial
order shipments, or synthesis failures as an acceptable business
practice. Ansa strives to become the trusted partner in DNA
synthesis by reliably building and delivering the complex and
challenging DNA sequences scientists need to advance their
research,” said Jason T. Gammack, CEO of Ansa Biotechnologies.
“With this product launch, we look forward to empowering more
scientists with the ability to let their imaginations run free,
which will drive the next wave of breakthroughs across healthcare,
life science research, and other industries powered by synthetic
DNA.”
Live Webinar
Ansa Biotechnologies is hosting a webinar to share recent
application data and provide additional details about how Ansa
Clonal DNA and Ansa DNA Fragments can help accelerate
innovation.
Complex DNA Synthesis for Your Most Ambitious
Projects Presenters: Jaymin Patel, UC Berkeley, and Eric
Estrin, Ansa Biotechnologies Date and time: August 6, 2024,
12:00 pm ET Registration: ansabio.com/webinar
For more information on Ansa Clonal DNA and Ansa DNA Fragments,
please visit ansabio.com/products.
About Ansa Biotechnologies
Ansa Biotechnologies enables customers to push the limits of
their scientific projects by delivering DNA sequences that can be
difficult or even impossible to manufacture with legacy synthesis
methods. Ansa’s products are powered by the company’s proprietary
synthesis technology, which enables ultra-rapid, assembly-free
enzymatic production of complex DNA sequences. This novel approach
is poised to accelerate innovation across healthcare, life science
research, and other industries powered by synthetic DNA. Ansa is
headquartered in Emeryville, CA. For more information, visit
ansabio.com or follow us on X and LinkedIn.
Ansa Biotechnologies and the Ansa Biotechnologies logo are
trademarks of Ansa Biotechnologies, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240730483148/en/
Media Contact Andrew Noble (415) 722-2129
andrew@bioscribe.com